Journal
ATHEROSCLEROSIS
Volume 254, Issue -, Pages 249-253Publisher
ELSEVIER IRELAND LTD
DOI: 10.1016/j.atherosclerosis.2016.08.038
Keywords
Coronary artery calcification; Lipids and lipoprotein metabolism; Hypercholesterolemia
Funding
- ISCIII-Subdireccion General de Evaluacion y Fomento de la Investigacion [PI12/01289]
- Fundacion Hipercolesterolemia Familiar (Spain)
- BQR
- Allocation de Recherche Chaire Mixte (Inserm-Universite)
- Programme de Recherche Hospitaliere en Sante - Projet CHOPIN (Agence Nationale de la Recherche)
Ask authors/readers for more resources
Background and aims: We aimed to assess whether elevated PCSK9 and lipoprotein (a) [Lp(a)] levels associate with coronary artery calcification (CAC), a good marker of atherosclerosis burden, in asymptomatic familial hypercholesterolemia. Methods: We selected 161 molecularly defined FH patients treated with stable doses of statins for more than a year. CAC was measured using the Agatston method and quantified as categorical variable. Fasting plasma samples were collected and analyzed for lipids and lipoproteins. PCSK9 was measured by ELISA, Lp(a) and apolipoprotein (a) concentrations by inmunoturbidimetry and LC-MS/MS, respectively. Results: Circulating PCSK9 levels were significantly reduced in patients without CAC (n = 63), compared to those with CAC (n = 99). Patients with the highest CAC scores (above 100) had the highest levels of circulating PCSK9 and Lp(a). In multivariable regression analyses, the main predictors for a positive CAC score was age and sex followed by circulating PCSK9 and Lp(a) levels. Conclusions: In statin treated asymptomatic FH patients, elevated PCSK9 and Lp(a) levels are independently associated with the presence and severity of CAC, a good predictor of coronary artery disease. (C) 2016 Elsevier Ireland Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available